Biologics for Endocrine/Metabolic: 60.0% of denials overturned
In 20 California IMR decisions from 2020 to 2025, reviewers overturned 12 (60.0%). In the last five years: 61.1% of 18. 17 were medical-necessity disputes, 3 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 1 | 100.0% |
| 2022 | 4 | 25.0% |
| 2023 | 2 | 50.0% |
| 2024 | 5 | 100.0% |
| 2025 | 6 | 50.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 7 | 42.9% | 60.0% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 3 | 100.0% | 60.0% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 3 | 33.3% | 60.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Repatha. Given this patient’s documented low-density lipoprotein cholesterol (LDL-C) levels, the patient clearly meets accepted guidelines for cholesterol lowering therapy. Repatha is typically indicated if a patient has failed to reach the target LDL-C with statin plus ezetimibe, or if the patient has met the criteria for …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Praluent 150mg every two weeks. In this case, the patient has a history of familial hyperlipidemia. The record establishes that the patient’s low-density lipoprotein (LDL) was far from goal even when the patient was on statin medication. Other medications, have a relatively …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Pertzye.The U.S. Food and Drug Administration (FDA) has approved pancrelipase under the brand name Pertzye for the treatment of exocrine insufficiency in patients diagnosed with cystic fibrosis. In this case, the patient has a history of cystic fibrosis and exocrine pancreatic insufficiency. …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Repatha. In this case, the patient has a history of hyperlipidemia, obstructive sleep apnea, coronary artery calcification, fatty liver, and a prominent ascending thoracic aorta. However, there is a lack of documentation confirming the patient’s statin intolerance. Elevated creatinine phosphokinase levels can …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials for Endocrine/Metabolic overturned?
In 20 California IMR decisions from 2020 to 2025, reviewers overturned 12 (60.0%). In the last five years: 61.1% of 18. 17 were medical-necessity disputes, 3 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.